

Legacy COPD project across Black Country

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

Black Country ICB and GSK are undertaking a Joint Working project. National Services for Health Improvement (NSHI Ltd) are delivering this therapy review service on behalf of GSK.

The aims are to:

- Validate the COPD disease register in participating practices
- Ensure alignment to national and regional COPD management and prescribing guidelines ‘COPD Inhaler Treatment Guidelines’
- Align to national prescribing strategy Investment and Impact Fund ‘Help create a more sustainable NHS’ enhanced service where clinically appropriate for patients
- Improve standard of care for COPD patients through use of Lunghealth and mentorship
- Support the NHS with Core20PLUS5 priorities aligned to COPD.

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project is planned to run from January 2023 to November 2023.

Intended Benefits:

Patients	<ul style="list-style-type: none"> • Full COPD review in line with regional guidelines based on GOLD risk stratification to ensure that at risk patients are prioritised for review. • Optimisation of both non-pharmacological & pharmacological management. • Potentially fewer COPD exacerbations, out of hours/A&E visits and hospital admissions. • Better informed about COPD management and treatment options leading to potentially greater concordance with therapy. • COPD managed in accordance with current best practice clinical guidance. • Better experience of the healthcare system – access to a NSHI respiratory Nurse specialist and/or upskilled primary care clinician at their own GP practice
NHS	<ul style="list-style-type: none"> • Validation of the COPD register and signposting of patients for further investigation for patients who may not have COPD or may have other co-existing conditions which may remain, as yet, undiagnosed. • Support with patient identification and risk stratification. • Additional nurse resource support. • Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting learning for sustainability. • Insight into COPD population at practice and local healthcare economy level to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care. • Opportunity to upskill primary care doctors and nurses. • An environment to support the delivery of improved health outcomes for the COPD patient population. • Potential reduction in COPD-related interventions, including hospital admissions. • Prescribing in line with national and local sustainability aspirations where clinically appropriate for patients.
GSK	<ul style="list-style-type: none"> • Broadening of the professional network. • Demonstrate partnership working. • Potential increase in prescribing of on-formulary dry powder inhaler products within class if clinically appropriate for patients, aligned to the sustainability agenda – which may include GSK products

GlaxoSmithKline (UK Ltd) and NHS Black Country ICB Executive Summary

	<ul style="list-style-type: none">• Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme.• Increase in the appropriate use of medicines licensed for COPD aligned to regional or national guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies.• Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care; and• Helps GSK to live its value of being a patient-focussed company
--	---